BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

Mar 11 2012NewsGuard 100/100 Score
The German- Federal Institute for Drugs and Medical Devices (BfArM) has granted Moberg Derma approval to initiate a clinical phase I trial for Limtop. Limtop is an innovative formulation of an immunomodulatory compound with potential to treat actinic keratosis, genital warts and basal cell carcinoma. The objective is a product with short treatment duration, an improved safety profile and an efficacy similar to or better than that of competing preparations.

"Limtop has the potential to make a real difference for many patients who currently suffer significant side effects, and we are now looking forward to test the formulation clinically. The results from the Phase I study are expected in the second quarter of 2012", say Peter Wolpert, CEO and founder of Moberg Derma.

Source Moberg Derma

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

FDA strengthens AI regulation to ensure patient safety and innovation in healthcare
Expanding access to GLP-1 weight-loss drugs could save thousands of lives
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy
Squid-inspired technology could replace needles for medications and vaccines
Small Solutions for Big Problems in Drug Discovery and Delivery
Small brain-penetrating molecule offers hope for treating aggressive brain tumors
Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder